Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: volociximab, atn-161, pf-04605412 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 636 | 0.91 |
| pathways Reactome | 9 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 3617
Sealed predictions
- ITGA5 in dopamine neurons, braak-0.46 (p 0.217) → -0.40 (p 0.284)receipt 3624
Swarm cases
receipt 3624: ITGA5 in dopamine neurons, braak
- power
- full sample -0.34 (p 0.170, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.55 (p 0.018, n 18). not the mix.
- skeptic
- leave-one-out range -0.48 to -0.24, sign flips 0; without severely affected donors -0.34 (p 0.170, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGA5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts